Figure 7.
DC vaccination with identified mesothelin epitopes protects animals against the development of pancreatic cancer. Bone marrow‐derived dendritic cells generated from C57BL/6 mice were pulsed with 300 μg/mL of either Meso351358, or Meso612619, or the SIINFEKL peptide. Subcutaneous injections (0.1 ml_) of 2 × 105 cells were given in each hind limb on days 0 and 7. Animals were challenged s.c. with 2.5 × 105 Panc02 cells on day 14. Mice were followed twice per week for the development of tumor. The data are presented as Kaplan‐Meier survival curves that indicate the percentage of tumor‐free animals as a function of time after tumor inoculation. Data are represented as results obtained from experiments with at least 10 mice per group (p= 0.0145 for mice treated with Meso612619 vs. control peptide, and p= 0.0539 for mice treated with Meso351_358 vs. control peptide).